This was a multicenter, open-label, randomized, crossover trial in subjects with MS who were already taking a stable dose of baclofen (up to 80 mg/day) for spasticity. The trial was designed to assess subject preference for Kemstro or conventional baclofen. At Visit 1, subjects were screened, and if qualified, were randomly assigned to one of two following treatment sequences: Kemstro/conventional baclofen or conventional baclofen/Kemstro.

Condition	Intervention	Phase
Multiple Sclerosis	Drug: Kemstro	Phase III

Ages Eligible for Study:  18 Years   -   65 Years,  Genders Eligible for Study:  Both

Criteria

Inclusion Criteria:

• stable dose of baclofen

Exclusion Criteria:

• not stable dosing

Wisconsin
      Schwarz, Mequoin,  Wisconsin,  United States

Study chairs or principal investigators

Patricia Witt,  Study Director,  Schwarz Pharma   

Study ID Numbers:  SP843
Last Updated:  August 30, 2005
Record first received:  August 29, 2005
ClinicalTrials.gov Identifier:  NCT00139789
Health Authority: United States: Institutional Review Board
ClinicalTrials.gov processed this record on 2005-09-13